Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06391034 · ClinicalTrials.gov registry record · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Robert Bok, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT06391034: Recruiting Phase 2 study of Prostate Cancer, sponsored by Robert Bok, MD, PhD.
NCT06391034 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Robert Bok, MD, PhD. The registered enrollment target is 161 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06391034, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Robert Bok, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Primary Outcome
A signal-to-noise ratio is defined as a MR/spectroscopy parameter, consisting of the HP C13-Pyruvate or Lactate signal (peak) relative to background noise level (baseline) in MRI spectra of the tissue.
Conditions Studied
Interventions
- DRUG hyperpolarized pyruvate +/-urea (13C/15N)
- RADIATION Non-investigational External beam radiotherapy (EBRT)
- PROCEDURE Radiotherapy (RT)
- PROCEDURE Multi-parametric magnetic resonance imaging (mpMRI)
- BIOLOGICAL Non-interventional hormone therapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 2 |
What NCT06391034 shows while recruiting
NCT06391034 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which hyperpolarized pyruvate +/-urea (13C/15N) is the first listed.
NCT06391034 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06391034 about?
NCT06391034 is a clinical study titled "Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer". This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
What is the current status of trial NCT06391034?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2024-09-24. Estimated completion is 2032-10-31.
What conditions does trial NCT06391034 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06391034?
The interventions under investigation include: hyperpolarized pyruvate +/-urea (13C/15N) (DRUG), Non-investigational External beam radiotherapy (EBRT) (RADIATION), Radiotherapy (RT) (PROCEDURE), Multi-parametric magnetic resonance imaging (mpMRI) (PROCEDURE), Non-interventional hormone therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT06391034?
This trial is sponsored by Robert Bok, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06391034 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06391034's enrollment target sits among peer trials
161 253rd of 735 higher than 481 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT07144826 · 161 participants · Early Phase 1
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI